Role of Dopamine Receptors in Primary Focal Dystonias

Healthy Clinical Trial

Official title:

Role of Dopamine Receptors in Primary Focal Dystonias

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01373840
• Other study ID #: 201102481
• Status: Completed
• Start date: September 2011
• Est. completion date: April 2016

Study information

• Verified date: May 2018
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Age >20

• Male or Female

• Any race or ethnicity

• Primary focal dystonia (arm or cranial)

• Ability to give informed consent

Exclusion criteria:

• Family history of dystonia

• Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding

• Exposure to radiation therapy

• Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc.

• History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase

• History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine).

• Active depression (Beck Depression Inventory_II >14)

• Cognitive impairment (Mini-Mental State Score <27)

• CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study

• History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.

Related Conditions & MeSH terms

• Dystonia
• Dystonic Disorders
• Focal Dystonias
• Healthy

Locations

Country	Name	City	State
United States	Washington University	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States,